Disease · MONDO_0017604

marginal zone lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. marginal zone lymphoma. Diseases, record MONDO_0017604. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017604

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: marginal zone lymphoma; Open Targets
Open Targets ID: MONDO_0017604; Open Targets
Other names: MZBCL, MZL, lymphoma of marginal zone B cell, marginal zone B cell lymphoma; Open Targets
Disease Ontology: DOID:0050748; Disease Ontology
NCI Thesaurus: C4341; NCI Thesaurus
Orphanet: ORPHA:300912; Orphanet
Highest stage of its drugs: Approval, for 2 of its 92 drugs, from FDA and TTD; Open Targets

Drugs92

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
UMBRALISIB	CHEMBL3948730	Small molecule	Approval	TTD	3	2	2	Drugs and targets
UMBRALISIB TOSYLATE	CHEMBL3989869	Small molecule	Approval	FDA	1	0	0	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	57	57	56	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
ORELABRUTINIB	CHEMBL4650321	Small molecule	Phase 3	ClinicalTrials.gov	19	19	19	Drugs and targets
OBINUTUZUMAB	CHEMBL1743048	Antibody	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
ZANUBRUTINIB	CHEMBL3936761	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
BENDAMUSTINE	CHEMBL487253	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
IBRUTINIB	CHEMBL1873475	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets

1 to 10 of 92

See all 92 drugs

Targets103

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	8	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
PIK3CD	PI3-kinase class I	8	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Approval	https://conductscience.org/library/genes/5293	Drugs and targets
BTK	Tyrosine-protein kinase BTK	7	Tyrosine-protein kinase BTK inhibitor	Phase 3	https://conductscience.org/library/genes/695	Drugs and targets
CD3D	T cell surface glycoprotein CD3	4	T cell surface glycoprotein CD3 binding agent	Phase 3	https://conductscience.org/library/genes/915	Drugs and targets
CD3E	T cell surface glycoprotein CD3	4	T cell surface glycoprotein CD3 binding agent	Phase 3	https://conductscience.org/library/genes/916	Drugs and targets
CD3G	T cell surface glycoprotein CD3	4	T cell surface glycoprotein CD3 binding agent	Phase 3	https://conductscience.org/library/genes/917	Drugs and targets
SYK	Tyrosine-protein kinase SYK	4	Tyrosine-protein kinase SYK inhibitor	Phase 2	https://conductscience.org/library/genes/6850	Drugs and targets
CD19	B-lymphocyte antigen CD19	3	B-lymphocyte antigen CD19 binding agent	Phase 3	https://conductscience.org/library/genes/930	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	3	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets

1 to 10 of 103

See all 103 targets

Trials139

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04680052	A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.	Phase 3	654	2025-04-04	Follicular Lymphoma, Marginal Zone Lymphoma	LENALIDOMIDE, RITUXIMAB, TAFASITAMAB	Its record names the disease	ClinicalTrials.gov
NCT01996865	Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.	Phase 3	503	2025-07-10	Lymphoma, Non-Hodgkin	LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01974440	A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma	Phase 3	403	2023-04-14	Lymphoma	BENDAMUSTINE, CYCLOPHOSPHAMIDE, DOXORUBICIN, IBRUTINIB, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01938001	Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)	Phase 3	358	2019-08-13	Lymphoma, Non-Hodgkin	LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01799889	Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies	Phase 2	326	2020-09-23	Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma	ENTOSPLETINIB	Its record names the disease	ClinicalTrials.gov
NCT00305682	Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant	Phase 2	295	2020-11-02	Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes	CYCLOPHOSPHAMIDE, FLUDARABINE, MYCOPHENOLATE MOFETIL, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03078855	A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma	Phase 3	211	2024-09-04	Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma	ERGOCALCIFEROL, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03768505	Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)	Phase 2	169	2024-02-01	Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma	ZANDELISIB	Its record names the disease	ClinicalTrials.gov
NCT01882803	A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma	Phase 2	129	2018-11-20	Indolent Non-Hodgkin Lymphoma	DUVELISIB	Its record names the disease	ClinicalTrials.gov
NCT02180711	Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma	Phase 1/2	113	2025-10-15	Non Hodgkin Lymphoma	ACALABRUTINIB, LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 139

See all 139 trials

Comparisons in its trials27

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: deaths from any cause	61 of 201	65 of 202	403	NCT01974440	Trial comparisons
Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	197 of 199	199 of 201	400	NCT01974440	Trial comparisons
Placebo + Chemoimmunotherapy (CIT) vs Ibrutinib + CIT: serious adverse events	76 of 199	113 of 201	400	NCT01974440	Trial comparisons
Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo: deaths from any cause	27 of 178	47 of 180	358	NCT01938001	Trial comparisons
Rituximab + Lenalidomide (R^2) vs Rituximab + Placebo: serious adverse events	45 of 176	25 of 180	356	NCT01938001	Trial comparisons
Vitamin D Plus Rituximab vs Placebo Plus Rituximab: All-Cause Mortality	4 of 135	3 of 71	206	NCT03078855	Trial comparisons
Vitamin D Plus Rituximab vs Placebo Plus Rituximab: deaths from any cause	4 of 135	3 of 71	206	NCT03078855	Trial comparisons
Vitamin D Plus Rituximab vs Placebo Plus Rituximab: serious adverse events	16 of 135	9 of 71	206	NCT03078855	Trial comparisons
Vitamin D Plus Rituximab vs Placebo Plus Rituximab: Number of Participants With Treatment Response at 13 Weeks	113 of 135	59 of 70	205	NCT03078855	Trial comparisons
Rituximab Plus Zandelisib vs Rituximab Plus Chemotherapy: Number of SAEs (Zandelisib When Combined With Rituximab)	12 of 41	8 of 41	82	NCT04745832	Trial comparisons

1 to 10 of 27

See all 27 comparisons in its trials

Papers from its trials53

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30901302	RESULT	1	PubMed
30897038	RESULT	1	PubMed
19770386	RESULT	1	PubMed
19344412	RESULT	1	PubMed
19167681	RESULT	1	PubMed
15613697	RESULT	1	PubMed
42875607	DERIVED	1	PubMed
42827116	DERIVED	1	PubMed
42782312	DERIVED	1	PubMed
42462111	DERIVED	1	PubMed

1 to 10 of 53

See all 53 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017604

GET https://conductscience.org/api/diseases/v1/MONDO_0017604/drugs?page=2

API reference For AI assistants